Skip to main content

Table 2 Inhibition of tritium labelled natural nucleoside and nucleobase uptake and metabolism by selected analogs*

From: Inhibition of Mycoplasma pneumoniae growth by FDA-approved anticancer and antiviral nucleoside and nucleobase analogs

  [3H]-dT [3H]-Ura [3H]-Hx [3H]-Gua [3H]-Ade
  Total uptake Incorporation Total uptake Incorporation Total uptake Incorporation Total uptake Incorporation Total uptake Incorporation
None 7.6±0.5 97.5±0.5 0.20±0.003 40±5 0.050± 0.001 62±7 0.9±0.05 56±3 0.62±0.1 44±1
Dipyridamole 7.2±1.1 97.0±1.3 0.20±0.003 38±6 0.008± 0.001 44±3 0.09±0.002 56±6 0.67±0.1 47±1
6-TG 7.9±0.6 97.4±0.7 0.21±0.003 39±8 0.005 ± 0.0004 43±6 0.080±0.002 67±3 0.66±0.1 46±3
TFT 18.2±0.6 97.4±0.5 0.11±0.002 27±0.2 0.011± 0.001 67±1 0.19±0.02 85±4 0.43±0.01 48±2
5FdU 14.7±0.2 96.0±0.5 0.087±0.003 19±7 0.006± 0.001 76±4 0.16±0.03 87±3 0.36±0.1 42±2
dFdC 5.2±0.4 96.7±1.1 0.12±0.001 26±6 0.009±0.0002 67±7 0.10±0.02 90±6 0.41±0.08 39±8
  1. *Total uptake: percentage of radioactivity recovered in the cells divided by total radioactivity added to the growth medium.
  2. Incorporation: percentage of radioactivity in the acid insoluble fraction divided by total radioactivity recovered in the cells.